Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review

Lung cancer patients frequently develop brain metastases (BM). For example, approximately 30% of radically treated stage III non-small cell lung cancer (NSCLC) patients present with symptomatic BM in the course of their disease, despite being treated with radical chemoradiotherapy[1]. In metastatic NSCLC with an oncogenic driver, BM incidence is up to 60%[2]. BM incidence of small cell lung cancer (SCLC) patients is even higher (up to 80% at autopsy)[3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research